Open AccessPB2021: QUALITY OF LIFE AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB‐LENALIDOMIDE‐DEXAMETHASONE (IRD): RESULTS OF A REAL‐WORLD EVIDENCE STUDY
Author(s) -
Ionova T.,
Vinogradova O.,
Kochkareva Y.,
Ado E.,
Kaplanov K.,
Shirokova M.,
Shelekhova T.,
Levanov A.,
Kopylova A.,
Li O.,
Mitina T.,
Rukavitsyn O.,
Simashova P.,
Anchukova L.,
Babich E.,
Dasheeva D.,
Demchenkova M.,
Dubov S.,
Esenina T.,
Ivanova L.,
Kravchuk T.,
Rimashevskaya E.,
Saraeva N.,
Savinova M.,
Volkova S.,
Porfirieva N.,
Nikitina T.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850916.45282.84
Subject(s) - medicine , lenalidomide , ixazomib , adverse effect , quality of life (healthcare) , multiple myeloma , carfilzomib , nursing